The GenCRISPR™ Cas9 v1.2 can be formed with the guide RNA into a ribonucleoprotien (RNP) complex. The use of an RNP complex to perform gene editing has been shown to reduce the challenges encountered with other CRISPR gene editing techniques such as viral and plasmid delivery. Challenges include off-target effects, cell viability and transcription/translational challenges. GenCRISPR™ Cas9 v1.2 is a tag free nuclease produced by expression in an E. coli strain carrying a plasmid encoding the Cas9 gene from Streptococcus pyogenes with a biparticle nucleus localization signal (BPNLS) at N-terminal and a nucleoplasmin nucleus localization signal (nucleoplasmin NLS) at C-terminal. It has been reported that BPNLS and nucleoplasmin NLS are able to improve the gene editing efficiency. |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
| Key Features | High gene editing efficiencies: Consistent high editing efficiency in in-vitro and in-vivo. Tag-free: Amino acid is free from additional tagging amino acid. DNA-free: No external DNA added to the system. |
| gRNA-dependent double-stranded DNA cleavage |
| Source | Recombinant Cas9 with a BPNLS at N-terminal and a nucleoplasmin NLS at C-terminal expressed by E.coli |
| Species | Streptococcus pyogenes |
| PAM | NGG |
| Tag | Tag-free |
| Molecular Weight | ~160 kDa |
| Concentration | 4 mg/ml |
| Active temperature | This Cas9 is active at 37°C. |
| Formulation | Supplied as a solution of 25 mM Tris, 300 mM NaCl, 0.1 mM EDTA, 50% glycerol, pH 8.0. |
| Storage & Stability | This product remains stable for 12 months at -20°C. Avoid repeated freeze-thaw cycles. |
| Appearance | Clear, colorless liquid |
| Purity | ≥ 90% as analyzed by SDS-PAGE |
| Concentration | 4 mg/ml±10% |
| Bioactivity | ≥ 90% |
| Residual DNase | Non-specific DNase activity |
| Residual RNase | Non-specific RNase activity |
| Endotoxin Level | ≤ 100 EU/mg as analyzed by gel clotting method |